Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | recruiting | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06386315 | Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma | recruiting | Phase 2 | 112 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06839053 | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07545603 | Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma | recruiting | Phase 2 | 65 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma(LINKER-MM1) | recruiting | Phase 1 / Phase 2 | 387 | Regeneron PharmaceuticalsINDUSTRY | 7 | Apr 20, 2026 | clinicaltrials |
| NCT05519579 | Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05909059 | CAR T-cell Therapy in Patients With Renal Dysfunction | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07496229 | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | recruiting | Phase 1 / Phase 2 | 165 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | recruiting | Phase 1 / Phase 2 | 152 | Curis, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT06378190 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology(TranspoCART19) | recruiting | Phase 1 / Phase 2 | 27 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03398161 | Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05336383 | Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06839456 | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | recruiting | Phase 1 / Phase 2 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | recruiting | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 4 | Apr 15, 2026 | clinicaltrials |
| NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | recruiting | Phase 2 | 44 | Jonathan BrammerOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05996185 | Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | recruiting | Phase 2 | 22 | Yale UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies(ADAPT-HEM) | recruiting | Phase 1 / Phase 2 | 96 | Beijing BiotechINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07525466 | Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) | recruiting | Phase 1 / Phase 2 | 25 | Beijing Tongren HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05183854 | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial | recruiting | Phase 2 | 61 | University of UtahOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07319676 | Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 30 | National University Hospital, SingaporeOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | recruiting | Phase 2 | 70 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03587844 | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | recruiting | Phase 2 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06536413 | ATRA and Carfilzomib in Plasma Cell Myeloma Patients(ATRA) | recruiting | Phase 1 / Phase 2 | 42 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07509086 | IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia | recruiting | Phase 2 | 25 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04512534 | Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma(Sincerely20) | recruiting | Phase 2 | 51 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05257018 | R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse | recruiting | Phase 2 | 83 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07508605 | Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma(CAR/TRuC-T) | recruiting | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07059650 | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) | recruiting | Phase 1 / Phase 2 | 150 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07234487 | Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL | recruiting | Phase 2 | 178 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06104592 | Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL | recruiting | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05898646 | Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial | recruiting | Phase 2 | 96 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06880913 | Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07499271 | Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation | recruiting | Phase 2 | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)(NexCAR19) | recruiting | Phase 2 / Phase 3 | 40 | Health Institutes of TurkeyOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR) | recruiting | Phase 2 | 720 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 2 | 75 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | recruiting | Phase 1 / Phase 2 | 93 | Stephan Grupp MD PhDOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05702853 | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | recruiting | Phase 1 / Phase 2 | 27 | Medical University of South CarolinaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06915246 | A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma | recruiting | Phase 2 | 49 | VIVUS LLCINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05388006 | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 27 | Mayo ClinicOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06847269 | CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia | recruiting | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493148 | Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL | recruiting | Phase 2 | 50 | Ou Bai, MD/PHDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT06793189 | MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL | recruiting | Phase 2 | 145 | Ruijin HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06985485 | Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy | recruiting | Phase 2 | 26 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07489534 | Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction | recruiting | Phase 2 | 25 | Daihong LiuOTHER | 1 | Mar 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 22, 2026source: clinicaltrials